Monoclonal antibodies are a therapeutic agent under investigation for the treatment of COVID-19 and created by identifying pathogen-specific B-cells of patients who have recently recovered from an infection or by utilizing mice genetically modified to have an immune system. The genes of immune globulin heavy and light chains are recovered after the identified B cells then expressed to produce monoclonal antibodies.